Related Experiment Videos
The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids
D J Powell1, J Russell, K Nibu
1Department of Otolaryngology-HNS Thomas Jefferson University Kimmel Cancer Institute, Jefferson Medical College, Philadelphia, Pennsylvania 19107, USA.
Cancer Research
|December 16, 1998
Summary
Researchers developed a mouse model to study papillary thyroid carcinoma (PTC). Transgenic mice expressing RET/PTC3 developed thyroid tumors and metastasis, aiding in understanding PTC mechanisms.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Background:
- Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy in the U.S.
- RET/PTC fusion proteins are implicated in PTC development, but their mechanisms are poorly understood.
- RET/PTC3 is frequently found in solid tumors and radiation-induced pediatric thyroid cancer.
Purpose of the Study:
- To investigate the molecular mechanisms of RET/PTC fusion protein action in thyroid cancer.
- To create a mouse model for studying papillary thyroid carcinoma initiation and progression.
Main Methods:
- Generated transgenic mice expressing human RET/PTC3 exclusively in the thyroid gland.
- Utilized a molecular genetic strategy to study thyroid disease mechanisms.
Main Results:
- Transgenic mice developed thyroid hyperplasia.
- These mice exhibited solid tumor variants of papillary carcinoma.
- Metastatic cancer was observed in the mouse model.
Conclusions:
- The RET/PTC3 transgenic mouse model effectively recapitulates key features of human papillary thyroid carcinoma.
- This model will be instrumental in deciphering the molecular and biological mechanisms underlying PTC and its histological variations.